Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Pharvaris N.V.
Pharvaris N.V. News
Jun 27, 2025 - globenewswire.com
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
Jun 16, 2025 - globenewswire.com
Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress
Pharvaris N.V. Quantitative Score
About Pharvaris N.V.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Pharvaris N.V. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Pharvaris N.V. Financials
Table Compare
Compare PHVS metrics with: | |||
|---|---|---|---|
Earnings & Growth | PHVS | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | PHVS | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | PHVS | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | PHVS | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Pharvaris N.V. Income
Pharvaris N.V. Balance Sheet
Pharvaris N.V. Cash Flow
Pharvaris N.V. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Pharvaris N.V. Executives
| Name | Role |
|---|---|
| Mr. Berndt Axel Edvard Modig CPA, M.B.A. | Co-Founder, Chief Executive Officer & Executive Director |
| Ms. Annick Deschoolmeester | Chief Human Resources Officer |
| Dr. Peng Lu M.D., Ph.D. | Chief Medical Officer |
| Mr. David W. Nassif J.D. | Chief Financial Officer, Chief Legal Officer & Corporate Secretary |
| Dr. Anne A. Lesage Ph.D. | Chief Early Development Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Berndt Axel Edvard Modig CPA, M.B.A. | Co-Founder, Chief Executive Officer & Executive Director | Male | 1959 | 649.77K |
| Ms. Annick Deschoolmeester | Chief Human Resources Officer | Female | 1973 | -- |
| Dr. Peng Lu M.D., Ph.D. | Chief Medical Officer | 1978 | -- | |
| Mr. David W. Nassif J.D. | Chief Financial Officer, Chief Legal Officer & Corporate Secretary | Male | 1954 | -- |
| Dr. Anne A. Lesage Ph.D. | Chief Early Development Officer | 1961 | -- |